MR-proADM as prognostic factor of outcome in COVID-19 patients
Open Access
- 4 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 11 (1), 1-7
- https://doi.org/10.1038/s41598-021-84478-1
Abstract
Mid Regional pro-ADM (MR-proADM) is a promising novel biomarker in the evaluation of deteriorating patients and an emergent prognosis factor in patients with sepsis, septic shock and organ failure. It can be induced by bacteria, fungi or viruses. We hypothesized that the assessment of MR-proADM, with or without other inflammatory cytokines, as part of a clinical assessment of COVID-19 patients at hospital admission, may assist in identifying those likely to develop severe disease. A pragmatic retrospective analysis was performed on a complete data set from 111 patients admitted to Udine University Hospital, in northern Italy, from 25th March to 15th May 2020, affected by SARS-CoV-2 pneumonia. Clinical scoring systems (SOFA score, WHO disease severity class, SIMEU clinical phenotype), cytokines (IL-6, IL-1b, IL-8, TNF-α), and MR-proADM were measured. Demographic, clinical and outcome data were collected for analysis. At multivariate analysis, high MR-proADM levels were significantly associated with negative outcome (death or orotracheal intubation, IOT), with an odds ratio of 4.284 [1.893–11.413], together with increased neutrophil count (OR = 1.029 [1.011–1.049]) and WHO disease severity class (OR = 7.632 [5.871–19.496]). AUROC analysis showed a good discriminative performance of MR-proADM (AUROC: 0.849 [95% Cl 0.771–0.730]; p < 0.0001). The optimal value of MR-proADM to discriminate combined event of death or IOT is 0.895 nmol/l, with a sensitivity of 0.857 [95% Cl 0.728–0.987] and a specificity of 0.687 [95% Cl 0.587–0.787]. This study shows an association between MR-proADM levels and the severity of COVID-19. The assessment of MR-proADM combined with clinical scoring systems could be of great value in triaging, evaluating possible escalation of therapies, and admission avoidance or inclusion into trials. Larger prospective and controlled studies are needed to confirm these findings.Funding Information
- funds for speaking at symposia organized on behalf of Pfizer, Novartis, Merck, Angelini, Thermofischer, Biomerieux, Basilea, Correvio, Zambon, Hikma and Astellas.
This publication has 22 references indexed in Scilit:
- Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admissionCritical Care, 2019
- The early identification of disease progression in patients with suspected infection presenting to the emergency department: a multi-centre derivation and validation studyCritical Care, 2019
- Procalcitonin and MR-Proadrenomedullin Combination with SOFA and qSOFA Scores for Sepsis Diagnosis and Prognosis: A Diagnostic AlgorithmShock, 2018
- The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trialCritical Care, 2018
- Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsisJournal of Infection, 2018
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- Procalcitonin, MR-Proadrenomedullin, and Cytokines Measurement in Sepsis Diagnosis: Advantages from Test CombinationDisease Markers, 2015
- Evolving functions of endothelial cells in inflammationNature Reviews Immunology, 2007
- Respiratory monitoring.1990
- Respiratory MonitoringJAMA, 1990